M&A / Deals AZ forges ever-closer ties with China’s CSPC Pharma PharmaphorumAstraZeneca has returned to China's CSPC Pharma to fill its R D pipeline, reaching a new $1.77bn agreement to develop drugs for kidney diseases.Read full story pharminent July 2, 2026 (Last updated: July 3, 2026) Pharmaphorum AstraZeneca has returned to China’s CSPC Pharma to fill its R D pipeline, reaching a new $1.77bn agreement to develop drugs for kidney diseases. Read full story Post navigation Previous: Roche’s KRAS drug tops its rivals in lung cancer trialNext: Novartis receives European Commission approval for Itvisma for spinal muscular atrophy Related Stories M&A / Deals Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease asset pharminent August 12, 2026 M&A / Deals Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront pharminent August 11, 2026 M&A / Deals Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments pharminent August 7, 2026
